Investigator Initiated Studies

Oxford Immunotec is dedicated to supporting meaningful, independent clinical research conducted by qualified investigators that is consistent with our areas of interest and commitment to improving the care of patients with immune-regulated conditions. Oxford Immunotec may provide funding and other forms of support, such as product and testing services. All physicians, healthcare providers, researchers and institutions worldwide who are interested in conducting their own research are eligible to submit a study proposal.

All proposals are reviewed on their merit by a select review committee. Criteria for approval include scientific merit and alignment with Company areas of interest. Investigator and/or institution responsibilities include study design, execution and compliance with all institutional and regulatory requirements. Support is subject to resource availability and conditioned upon an approved study concept proposal, full study protocol and full execution of a research support agreement by both parties.

Areas of Interest

Including, but not exclusive of:

 

TB COVID Other
  • Studies to optimise further use of the T-SPOT.TB test as a means of diagnosis; for example (but not limited to), as a means of detecting disease progression, or for differentiating active versus latent TB infection
  • TB testing in COVID patients
  • TB testing in rheumatology, cancer, ulcerative colitis or Crohn’s disease patients receiving biologics
  • Vaccine studies in healthy populations
  • General studies in the elderly, paediatrics and patients with comorbidities and immunosuppressed
  • Acute phase infection with SARS-CoV-2
  • T cell behaviour – TB and SARS-CoV-2 co-infection
  • Prospective studies to explore performance of T-SPOT technology-based tests in immunosuppressed groups

CMV:

  • Interventional studies
  • Congenital CMV

 

For more information please click here to download the Investigator Initiated Study Proposal form. Please submit both the cover letter and study protocol to Oxford Immunotec Medical Affairs at researchstudies@oxfordimmunotec.com.